Search for: "PFIZER INC "
Results 1461 - 1480
of 1,505
Sorted by Relevance
|
Sort by Date
12 Nov 2017, 11:00 pm
A recurring issue in securities cases involves the question of when plaintiffs may rely on the presumption of reliance under the fraud on the market doctrine. [read post]
13 Jun 2013, 7:05 pm
Apple Inc. 12-1158Issue: (1) Whether the offer for sale and/or sale of a product that embodies a patented invention can directly infringe a method claim under 35 U.S.C. [read post]
18 Jan 2007, 7:53 pm
Pfizer Inc., No. [read post]
30 Aug 2016, 2:33 pm
Wyeth, Inc., Dr. [read post]
2 Aug 2014, 6:05 am
Sinai Hospital and Medical Center of Chicago, Inc., 807 N.E.2d 1026, 1033 (Ill. [read post]
7 Jun 2007, 10:52 am
Pfizer, Inc., 198 F. [read post]
26 Feb 2024, 6:41 am
The IMR reviewer noted that applicant had a history of auditory hallucinations, which were ameliorated with Geodon, demonstrating the efficacy of that medication and supporting its medical necessity. [ LexisNexis Commentary: This IMR is particularly interesting because the medication Geodon, which was at issue here, was the subject of a $301 million settlement between Pfizer, Inc. and the U.S. [read post]
13 Jan 2023, 3:00 am
National/Federal At Proud Boys Trial, U.S. [read post]
7 Mar 2008, 2:00 am
: (IPBiz), US: Proposals for the approval of generic biologics under consideration: (Pharmacapsules@Gowlings), US: A paradigm shift in obviousness for pharma, biotech: (IP Law360), US: USPTO’s Bruce Kisliuk addresses ACI Pharma/biotech patent claim drafting and prosecution conference: (Patent Docs), US: New bill to provide biotech companies Sarbanes-Oxley relief: (California Biotech Law Blog), US: Biotech and pharma companies spent millions on lobbying in 2007: (Patent… [read post]
1 Feb 2008, 12:00 am
: (IPBiz),State of the Union address 28 Jan 2008: statement regarding patenting human life: (IPBiz), (Patently-O),Alnylam Pharmaceuticals secures UK patent covering molecules that affect RNA interference: (SmartBrief),Doha style compulsory licences for exports: The politics…: (Spicy IP),Pushing to compulsory licensing: Pharma companies heading closer to Doha: (Spicy IP),Financial Express on the battle between big pharma companies and the generic… [read post]
23 Feb 2010, 6:16 am
Editor’s Note: John Olson is a founding partner of Gibson, Dunn & Crutcher’s Washington, D.C. office and a visiting professor at the Georgetown Law Center. [read post]
20 Dec 2023, 5:00 am
Monoclonal Antibodies Inc., 1985) protected large genus claims. [read post]
2 Sep 2022, 5:01 am
This new article of mine will be coming out next year in the Journal of Law and Religion, and I thought I'd serialize it here; there's still plenty of time for editing, so I'd love to hear people's feedback. [read post]
27 Apr 2007, 12:04 pm
By Hal WegnerBefore an overflow hearing room on an internationally available web broadcast, Chairman Howard Berman of the House Judiciary Subcommittee relevant to patents hosted a most informative and candid hearing yesterday afternoon joined by roughly ten of his committee colleagues, including Rep. [read post]
10 Jan 2020, 9:32 am
Goodman Distr., Inc., 694 F. [read post]
16 Aug 2009, 11:23 am
The best example of the downside of optionality was the sale of United Rentals Inc. where the buyer, Cerberus, unabashedly chose to pay the break fee rather than close, despite the absence of any material problem in the URI business. [read post]
6 Feb 2013, 9:00 pm
Then later in the summer, the DOJ moved to a 9 point compliance program in the Pfizer DPA. [read post]
15 Sep 2011, 4:06 am
Co., Inc., 480 Pa. 547, 559, 391 A.2d 1020, 1027 (1978). [read post]
2 May 2008, 7:00 am
: (Patent Baristas), US: How to avoid a permanent injunction: the lessons of Amgen v Hoffman-LaRoche: (Patent Docs), US: Jarvik Heart’s PTE request based on PMA shell/module submission dates flatlines; ruling on initiation of PTE ‘review period’ mirrors FDA policy for ‘fast track’ products: (FDA Law Blog) Pharma & Biotech - Products Kytril (Granisetron) – Exclusivity ‘parking’ still possible under… [read post]
22 Mar 2008, 2:00 am
: (IPBiz),US: Two remaining challenged WARF embryonic stem cell patents upheld in ex parte reexamination: (Holman's Biotech IP Blog), Pharma & Biotech - ProductsAricept (Donepezil) – USV wins appeal against USPTO decision: (Spicy IP),Celerex (Celecoxib) – CAFC decision in Celebrex patents dispute between Pfizer and Teva will cut patent term by one and a half years: (Patent Baristas), Inersan – Ranbaxy in-licenses Inersan to CD Pharma to market in… [read post]
